afamelanotide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-07. Numbers and descriptions here follow the published literature rather than marketing material.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
== Medical uses == Dielectric heating (diathermy) is used in medicine; the frequencies used typically lie in the ultrasonic, shortwave, and microwave ranges. Careless application, especially when the patient has implanted metal conductors (e.g. cardiostimulator leads), can cause burns of skin and deeper tissues and even death. Microwave damage to tissues can be intentionally exploited as a therapeutic technique, e.g. radiofrequency ablation and radiofrequency lesioning. Controlled destruction of tissue is performed for treatment of arrhythmia. Microwave coagulation can be used for some kinds of surgeries, e.g., stopping bleeding after a severe liver injury. Microwave heating seems to cause more damage to bacteria than equivalent thermal-only heating. However food reheated in a microwave oven typically reaches lower temperature than classically reheated, therefore pathogens are more likely to survive. Microwave heating of blood, e.g. for transfusion, is contraindicated, as it can cause hemolysis and hyperkalemia. Microwave heating is one of the methods for inducing hyperthermia for hyperthermia therapy. High-energy microwaves are used in neurobiology experiments to kill small laboratory animals (mice, rats) in order to fix brain metabolites without the loss of anatomical integrity of the tissue. The instruments used are designed to focus most of the power to the animal's head. The unconsciousness and death is nearly instant, occurring in less than one second, and the method is the most efficient one to fix brain tissue chemical activity.
Among the Buddhists there was a Tocharian (Tho-gar) king called Men-dre, or Polosi, or Ānandavarmā. He had the caves painted by restorers and painters: Mitradatta; Naravāhanadatta from the lands of the "naked ones" (Niganthas); Priyaratna from Romakam (Byzantine Empire); and other experts in restoration. The king of the Rgya-ser and King Men-dre's bodies were taken by Amitābha and he went to the land of bliss. When the son of the great king of Rgya-ser came to the fort of Mir-li, thanks to the power of prayer, all the "naked ones" (Niganthas) were killed by the followers of Kālacakra, and all of the Buddhist caves were restored. According to Sam van Schaik, "Mendre" could be the Indo-Greek king Menander, or the mythical king Manadhatṛ of Buddhist sources; "Polosi" could be a Chinese abbreviation for king Prasenajit; "Romakam" may be the Byzantine Empire; the "naked ones" would be the Niganthas. In Tibetan, the country named "Tho-gar" "Thod-kar" corresponds to Tokharistan (ancient Bactria).
Valve president and Half-Life director Gabe Newell coined the name "Gordon Freeman" during a conversation with the game's writer Marc Laidlaw in his car. Laidlaw had originally named the character "Dyson Poincaré", combining the names of physicist and philosopher Freeman Dyson and mathematician Henri Poincaré. The texture for Gordon's head was "too big of a job for just one person", so Valve designers combined references from four people. An earlier model of Gordon, known as "Ivan the Space Biker", had a full beard that was subsequently trimmed. Other iterations of Gordon's concept featured different glasses, a ponytail, and a helmet. Gordon wears a special full-body hazmat suit, known as the Hazardous Environment Suit (or HEV Suit). The suit is designed to protect the user from radiation, energy discharges, and blunt trauma during the handling of hazardous materials. The suit's main feature is its "high-impact reactive armor", an electrically powered armor system that, when charged, absorbs two-thirds of the damage that Gordon would ordinarily suffer in Half-Life and 80% in Half-Life 2. A fully charged suit can survive several dozen hits from small arms and even one direct hit from an RPG. The suit can be charged by various means, and has its own oxygen supply and medical injectors, such as morphine and a neurotoxin antidote. It comes with a built-in flashlight, a radio (which frequently picks up enemy communications), various tracking devices, a compass, and a Geiger counter.
=== Synthetic genomics === The formation of animals with a chemically manufactured (minimal) genome is another facet of synthetic biology that is highlighted by synthetic genomics. This area of synthetic biology has been made possible by ongoing advancements in DNA synthesis technology, which now makes it feasible to produce DNA molecules with thousands of base pairs at a reasonable cost. The goal is to combine these molecules into complete genomes and transplant them into living cells, replacing the host cell's genome and reprogramming its metabolism to perform different functions. Scientists have previously demonstrated the potential of this approach by creating infectious viruses by synthesising the genomes of multiple viruses. These significant advances in science and technology triggered the initial public concerns concerning the risks associated with this technology. A simple genome might also work as a "chassis genome" that could be enlarged quickly by gene inclusion created for particular tasks. Such "chassis creatures" would be more suited for the insertion of new functions than wild organisms since they would have fewer biological pathways that could potentially conflict with the new functionalities in addition to having specific insertion sites. Synthetic genomics strives to create creatures with novel "architectures," much like the bioengineering method. It adopts an integrative or holistic perspective of the organism.
=== Correcting for GPS signal errors === In the 1990s, NASA scientists at JPL developed software capable of correcting for GPS signal errors, enabling accuracy within inches; it is called Real-Time GIPSY (RTG). John Deere licensed the software and used it to develop self-driving farm equipment. As of 2016, as nearly 70% of North American farmland is cultivated by self-driving tractors, which rely on RTG that was developed at NASA. Another user of RTG is Comtech Telecommunications, which is a major provider of location-based services. This technology is used in cell phones so that 9-1-1 emergency callers can be located.
Sources: en.wikipedia.org
=== Cold Fusion 3 === Version 3, released in June 1997, brought custom tags, cfsearch/cfindex/cfcollection based on the Verity search engine, the server scope, and template encoding (called then "encryption"). Version 3.1, released in Jan 1998, added RDS support as well as a port to the Sun Solaris operating system, while ColdFusion studio gained a live page preview and HTML syntax checker.
It has been proposed that ubiquitin is the slowest-evolving protein identified to date. Ubiquitin contains seven lysine residues to which another ubiquitin can be ligated, resulting in different types of polyubiquitin chains. Chains in which each additional ubiquitin is linked to lysine 48 of the previous ubiquitin have a role in proteasome targeting, while other types of chains may be involved in other processes.
=== United States === Ochoa then went to the United States, where he again held many positions at several universities. Between 1940 and 1942, Ochoa worked for Washington University's School of Medicine. In 1942 he was appointed research associate in medicine at the New York University School of Medicine and there subsequently became assistant professor of biochemistry (1945), professor of pharmacology (1946), professor of biochemistry (1954), and chair of the department of biochemistry. In 1956, he became an American citizen. He was elected to both the United States National Academy of Sciences and the American Academy of Arts and Sciences in 1957. In 1959, Ochoa and Arthur Kornberg were awarded the Nobel Prize for Physiology or Medicine "for their discovery of the mechanisms in the biological synthesis of ribonucleic acid and deoxyribonucleic acid". He was elected to the American Philosophical Society in 1961. Ochoa continued research on protein synthesis and replication of RNA viruses until 1985, when he returned to now democratic Spain where he was a science advisor. Ochoa was also a recipient of U.S. National Medal of Science in 1978. Severo Ochoa died in Madrid, Spain on 1 November 1993. Carmen García Cobián had died in 1986. Long after his death, Spanish actress Sara Montiel claimed that she and Severo Ochoa were involved in a romantic relationship in the 1950s, as stated in an interview in Spanish newspaper El País: "The great love of my life was Severo Ochoa. But it was an impossible love. Clandestine.
==== Infrastructure and public works ==== On 10 May 2025, the Valenzuela 500 kV Interconnection Substation, considered the largest in the Paraguayan electrical system, was inaugurated. The project, carried out by the National Electricity Administration (ANDE), benefits approximately 770,000 users in Asunción, the metropolitan area, and departments such as Cordillera, Paraguarí, and Presidente Hayes. The project, with an investment of 79 million dollars financed by the Financial Fund for the Development of the River Plate Basin (Fonplata), forms part of a strategy to strengthen the National Interconnected System and advance regional energy integration. President Peña highlighted the importance of diversifying the country's energy matrix, promoting agreements with Argentina to continue the Aña Cuá works, as well as initiatives with Itaipu for the development of solar energy. He also promoted private-sector participation in electricity generation and distribution, and announced reforms to the Energy Law to facilitate that process.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.